The current treatment of patients with acute lymphocytic leukemia (ALL) is quite effective, but at a high price. The treatment can still cause health problems years later. That is why “milder” therapies are desperately needed.
In this proposal the researchers want to study whether the addition of immunotherapy to the standard treatment of acute lymphocytic leukemia improves the chances of survival and quality of life.
The researchers of this project want to know whether adding blinatumomab to the standard treatment of patients with ALL is useful. This concerns patients who start their first treatment after the diagnosis has been made.
This study will show whether adding blinatumomab to standard treatment increases the chance that the cancer survival without recurrence. Chances for treatment outcomes are much worse for patients with recurrence.